BACKGROUND: During the last decade, an inverse stage migration has been observed in radical prostatectomy series at tertiary centers. However, it remains unclear whether similar trends can also be observed in solely robotic practices, including nonreferral centers. The aim of this study was to investigate the clinical and pathological trends in robotic-assisted laparoscopic prostatectomy (RALP) enrollment in Belgium over a period of 6 years through an analysis of a prospective registry. METHODS: A prospective, multicenter database was constructed: consecutive patients undergoing RALP in Belgium from 2010 to 2015 were enrolled, and 7366 men were analyzed. Variations in clinical and pathological variables were explored as a function of the enrollment year with proportional odds for categorical variables and with linear regressions for continuous variables. RESULTS: Net increases were observed in the prostatespecific antigen levels, cT stage, and biopsy Gleason scores across the study years (P < .001). The rate of low-risk prostate cancer (PCa) decreased from 36% in 2010 to 21% in 2015, whereas the rate of intermediate-risk PCa rose from 47% to 58%, and the rate of high-risk PCa rose from 17% to 21%. In parallel, the pT2 stage rate decreased from 76% to 64%, and the rate of Gleason 6 (3 1 3) cases was reduced from 45% to 23% (P < .001). Conversely, the pT3a stage rate rose from 16% to 24%, the pT3b stage rate rose from 7% to 11%, and the rate of Gleason 7 (4 1 3) cases rose from 7% to 21% (P < .0001). Finally, more patients underwent node dissection, and positive lymph nodes were increasingly diagnosed (from 3% in 2010 to 7% in 2015). CONCLUSIONS: During the last 6 years of RALP implementation in Belgium, there was a significant increase in the enrollment of intermediate-and high-risk PCa patients. This yielded a significant increase in adverse pathological characteristics. These results suggest a paradigm shift in PCa treatment, with radical robotic surgery increasing for intermediate-and high-risk patients.
INTRODUCTION
Prostate cancer (PCa) is the most common noncutaneous malignancy for men in Europe. In Belgium, nearly 8000 new cases are diagnosed each year, and 89% of these cases present with stage I to III disease and may be considered candidates for radical local treatment. 1 As for surgery, robotic-assisted laparoscopic prostatectomy (RALP) is becoming the new standard of treatment for the local control of disease; it has oncologic outcomes comparable to those of the open approach. 2 In the early years of robotic-assisted surgery implementation, a selection bias in favor of low-risk patients was frequently present, and this was coupled with a historic increase in low-grade PCa detection due to prostate-specific antigen (PSA) screening. 3 This led to a higher incidence of low-risk disease in PCa patients being offered RALP in those discovery years. Today, however, with growing experience and more accurate patient risk stratification, several tertiary centers have observed a trend toward more advanced disease being treated. [4] [5] [6] [7] Moreover, there is growing evidence for the safety of active surveillance for select patients with low-risk disease, 8 and there are intriguing findings from focal therapy for select low-and intermediate-risk patients. 9 Moreover, large, long-term studies have found that although intermediateand high-risk patients always benefit from radical surgery versus watchful waiting, 10 ,11 the same is not true for men harboring low-risk PCa: immediate radical treatment is rarely beneficial for these men, 8, 10 and it exposes them to the morbidity of radical prostatectomy without a gain in survival. As such, indications for radical prostatectomy, open or minimally invasive, are shifting toward the treatment of higher grade, higher stage, and higher risk disease. [4] [5] [6] 12 In 2009, a collaboration across several Belgian academic departments, the Belgian Cancer Registry, and the reimbursement authority in Belgium (Rijksinstituut voor Ziekte-en Invaliditeitsverzekering/Institut National d'Assurance Maladie Invalidit e [RIZIV/INAMI]) gave birth to the Be-RALP Registry (Belgian Robotic-Assisted Laparoscopic Prostatectomy Registry) project, a prospective registry to which surgeons from across the country were invited to submit the clinical, pathological, and follow-up data for consecutive patients undergoing RALP with or without pelvic lymph node dissection (PLND). In times of economic crisis and evidence-based medicine, a surgical approach-especially a costly approach such as robotic surgery-must demonstrate its correct application to the right patients. 13 The aims of the current study were to analyze the changes in patient enrollment for RALP during the first 6 years of registry implementation and to evaluate time trends in the grade, stage, and risk groups of patients selected for RALP in Belgium.
MATERIALS AND METHODS
In October 2009, surgeons and centers performing RALP in Belgium were invited by the Belgian Cancer Registry and RIZIV/INAMI to submit clinical, pathological, and follow-up data for consecutive patients undergoing robotic prostatectomy. The registration of patient data was performed as part of obtaining reimbursement from RIZIV/INAMI for robotic material costs. The RALP procedures were performed at 25 academic, public nonacademic, and private hospitals. The data were electronically encoded in a prospective manner by 1 person at each center and transmitted to the Belgian Cancer Registry. Data were handled by the registry in accordance with strict privacy policies according to Belgian laws under the supervision of cancer registry professionals (N.V.D.). The data gathering was continued for 6 years and was closed on February 29, 2016 .
Patients were stratified into risk categories according to the D'Amico criteria 14 : they were considered to be at low risk if the PSA level was <10 ng/mL, the cT stage was 1c to 2a, and the biopsy Gleason score was 6; they were considered to be at intermediate risk if the PSA level was 10 to 20 ng/mL, the cT stage was 2b, or the biopsy Gleason score was 7; and they were considered to be at high risk if the cT stage was 2c, the PSA level was 20 ng/mL, or the biopsy Gleason score was 8. The cT stage was defined according to a digital rectal examination performed by a senior urologist. Prostate biopsies and RALP specimens were analyzed by a dedicated uropathologist at each center. Histologic grading was defined according to the Gleason system, and staging was described with the TNM classification. 15 A positive surgical margin (PSM) was defined as the presence of at least 1 malignant gland in contact with the inked surface of the specimen. When the lymphadenectomy status was unknown or the patients had undergone PLND but no nodes were found on pathology, the patients were classified as pNx. The Belgian Cancer Registry double-checked the correctness of the data from a number of patient files with respect to the input pathological variables because the registry also receives individual patient data directly and independently from the pathologists of each hospital. Differences in categorical variables were explored across enrollment years with a proportional odds model. Continuous variables were analyzed with a linear regression model to assess significant modifications across enrollment years. P .05 was considered statistically significant. Statistical analyses were performed with SAS 9.3 (SAS Institute, Inc).
RESULTS
Twenty-five centers across Belgium participated in patient data gathering. After the exclusion of men with incomplete data (n 5 1076), 7366 patients were available for the final analysis (Table 1) . Over the examined period of time, we observed a progressive increase in the adverse clinical characteristics of cancers for which operations were performed ( Table 2 ). In particular, the rate of cT3 to cT4 cancers increased from 3% to 11%, and the rate of PCa cases with a biopsy Gleason score of 8 rose from 8% to 17%. Moreover, we observed a net increase in the percentage of positive cores at biopsy: the proportion of patients for whom >50% of biopsies were positive for PCa grew from 17% in 2010 to 28% in 2015. This resulted in a global increase in the risk classification of men undergoing RALP in Belgium during the last 6 years: the proportion of low-risk patients decreased from 36% to 21% with consequent increases in intermediate-risk disease (from 47% to 58%) and high-risk disease (from 17% to 21%; all P values < .001; Fig. 1 ).
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Similarly to clinical characteristics, we found increases in pathological characteristic (Table 2) . Notably, the rate of organ-confined disease was reduced from 76% to 63% (P < .001), and there were increases in extracapsular extension (from 16% to 24%) and seminal vesicle invasion (from 7% to 12%; all P values < .001). The Gleason score on the final pathological examination also exhibited a progressive increase ( Fig. 2) : although the Gleason 6 (3 1 3) rate decreased from 45% to 23%, the Gleason 7 (4 1 3) PCa rate rose from 7% in 2010 to 21% in 2015. Exploring the surgical margin status, we found an overall PSM rate of 25%. The PSM rate was stable throughout 2010-2015, with no significant differences found (P 5 .13) across the analyzed years. When we evaluated differences within various pT stages, the PSM rate remained stable during the study years, with no significant variations detected (all P values > .39): the PSM rate ranged from 15% to 19% for pT2 disease, from 36% to 44% for pT3a disease, from 51% to 54% for pT3b disease, and from 64% to 100% for pT4 disease.
As for lymphadenectomy, the progressive trend toward the treatment of more advanced and aggressive disease was accompanied by an increase in the rate of patients undergoing PLND (Table 2 ). Although 21% of the men undergoing RALP in 2010 underwent concomitant PLND, in 2015, 43% of the patients underwent node dissection. This resulted in a rise in node-positive disease (pN1) from 3% in 2010 to 8% (P < .001) in 2015. We then explored PLND rates according to the D'Amico risk score. For low-risk disease, the PLND rate remained low (5%) across the study years. For intermediate-and high-risk disease, however, we recorded a significant increase in patients undergoing PLND as well as patients being found with node-positive disease on the final pathological analysis (Table 2) , with 8% of intermediate-risk patients and 12% of high-risk patients presenting with pN1 disease. Nonetheless, even in 2015, 43% of the patients with a high-risk profile and 49% of men harboring intermediate-risk PCa were still not being offered PLND at the time of RALP.
DISCUSSION
Medicine is constantly evolving, and so are the clinical presentations of our patients, the treatments, and the surgical techniques. 16 The massive increase in PCa detection that followed the introduction of PSA testing led to a significant rise in the number of prostatectomies performed in Europe and the United States in the 1990s; this was defined by some as the holocaust of the prostate. 17 This attitude led to the overtreatment of many indolent cancers (18) 199 (16) 204 (18) 261 (21) 332 (24) 3b 83 (7) 112 (8) 109 (9) 105 (10) 139 (11) 152 (11) 4 2 (1) 5 (1) 17 (1) 14 (1) 17 (2) ISUP III) 77 (7) 113 (9) 142 (12) 163 (15) 213 (17) 288 (21) and raised the question whether widespread PSA testing was still advisable. 18 As years passed, our understanding of PCa grew, and the selection of patients most likely to benefit from radical surgery became stricter. 19 In parallel, large active surveillance trials reported intriguing and hopeful results 20 and allowed us to further reduce the number of excessive radical surgeries. Recently, the ProtecT trial reported long-term results for 1643 men randomized to undergo radical surgery, radiotherapy, or surveillance for localized PCa. 8 For patients harboring Gleason 6 PCa, no significant difference in cancerspecific survival (3 deaths in the surgery and surveillance groups and 2 deaths in the radiotherapy group; P 5 .69) or in overall survival was observed across the 3 groups. Conversely, treatment-related side effects were highly prevalent after radical prostatectomy (this deeply affected continence and erectile function) and after radiotherapy (this led to significant bowel symptoms in comparison with surveillance). 21 These results shed light on the true impact of radical therapy on PCa and should be kept in mind when one is deciding the clinical strategy for PCa patients. Finally, magnetic resonance imaging (MRI) and MRI-guided biopsy are now entering the scene 22 and allowing better characterization of PCa before treatment planning, which has for decades been biased by the incongruity between biopsy and pathological specimens. In parallel with the evolution of PCa, robotics entered urologic surgery, and it is here to stay. 23 It was our hypothesis that the aforementioned facts led to a change from the initial trend of operating mainly for low-risk PCa patients to operating for higher risk PCa patients in Belgium. Therefore, to keep track of the evolution of robotic surgery and results nationwide, in October 2009, the national cancer registry began to prospectively record data for patients undergoing operations via a robotic approach. Globally, when the number of patients included in the Be-RALP registry is compared with the incidence of PCa in Belgium, it appears that the registry represents roughly 13% to 15% of all new cases, 1 although this estimation is preliminary and should be considered strictly indicative.
Overall, the global picture that we have obtained from our study is in favor of an inverse stage migration for RALP toward PCa candidates with higher stage and higher grade disease. Exploring biopsy specimens, we found a net increase in Gleason scores of 7 and 8 as well as significant growth in the percentage of positive biopsies: in 2015, 28% of patients had >50% positive biopsy cores, whereas 17% did in 2010. This is in line with recent studies of mainly open radical prostatectomies from several tertiary referral centers across the United States and Europe. 4, 6 Notably, we observed a significant decrease in Gleason 6 (3 1 3) scores (from 45% to 23%) with a concomitant rise in Gleason 7 (4 1 3) scores (from 7% to 21%). Moreover, when we analyzed tumor stages, the rate of organ-confined disease decreased from 76% to 63% with a significant rise in pT3 cases. The reasons for this change in patient enrollment are multiple and multifactorial. First, active surveillance is increasing in Europe, and as such, more patients with very low-risk and low-risk disease are advised to avoid or defer radical therapy, at least as a first option. 20 Second, the discovery years of RALP are now over, and the experience gained by many robotic surgeons is sufficient that RALP can be performed even in patients with locally advanced disease. 24 Although in the first years of such robotic approaches the absence of haptic feedback was considered a major limitation of robotics for dissecting a locally advanced tumor, this concept has now passed, and the PSM rates are generally comparable to those of open surgery, if not lower, even for pT3 to pT4 cancers. 25 Finally, the last years have witnessed a surge of multiparametric MRI for the detection and staging of PCa. 26, 27 Although not every center in Belgium has prompt access to MRI for all men with abnormal PSA results, many of our patients, especially in the academic setting, do undergo imaging before the decision to perform or not perform prostate biopsy is made. 28 Moreover, MRI-guided biopsy is increasingly being implemented in Belgium. 29 We speculate that the high negative predictive value of MRI 30 and the improved accuracy of MRIguided biopsy have reduced the detection of indolent cancers and ameliorated diagnostic accuracy. This may have led to a better selection of patients for active surveillance, with the correct patients with higher stage and higher grade PCa being directed to radical surgery. Clearly, this remains a speculative hypothesis and requires further investigation.
We also analyzed trends in PSMs after surgery and found an overall PSM rate of 25%, which is in line with multiple published studies. 25, 31 Although we did find nonsignificant reductions in the PSM rate for pT3a and pT3b (from 44% to 39% and from 64% to 51%, respectively), the global rate was not significantly decreased during the study period (P 5 .13). This finding most likely reflects the overall trend in stage migration, with more patients who are harboring locally advanced disease being offered RALP in Belgium, but there has been a reduction of PSMs in such patients. Because the pT stage is the most significant demonstrated risk factor for PSMs, 25 this is possibly responsible for the reported stable PSM rate in Belgium during the last 6 years.
The findings of our study are not dissimilar from those of other investigators [4] [5] [6] 32 ; however, it must be underlined that most of the cited studies come from single, high-volume tertiary centers with mostly open surgeries, whereas the results that we are reporting represent a nationwide trend across Belgium and include solely robotic surgeries. Bernie 3 1 3) cases dropping from 52.2% to 12.1%. 5 As for PLND, studies have suggested that with growing numbers of robotic procedures worldwide, PLND implementation has decreased. 33, 34 However, the robotic-assisted approach (in trained hands) has been demonstrated to achieve the same nodal yield as the open and laparoscopic approaches. [34] [35] [36] In the current study, we describe an increase in PLND implementation within the last 6 years. Moreover, with increasing pathological stage, patients were more likely to be found with positive nodes at the time of surgery. These findings are probably the result of both the inverse stage migration and the increasing robotic experience acquired by our surgeons during the last years, which has made extended PLND a standard procedure. Overall, 78% of our patients underwent extended PLND, whereas 18% underwent only limited dissection. However, in a preliminary analysis, extended PLND was increasingly being performed across the study years, with the rate reaching 88% in 2015 (P < .001). Similarly, the lymph node yield increased from a median of 13 (interquartile range, 9-15) in 2010 to 15 (interquartile range, 11-19) in 2015 (P < .001). Nonetheless, when we break down the data according to the D'Amico risk score, it appears that currently in Belgium, PLND is far from being implemented in all high-risk patients, as advised by guidelines: 76% of the high-risk patients were not offered PLND in 2010, and in 2015, 43% harboring high-risk disease still were not undergoing PLND despite current European Association of Urology recommendations. 37 The reasons for this finding remain unclear. Therefore, although PLND rates are increasing for intermediate-and high-risk PCa, a targeted strategy should be implemented in Belgium to make its application adequate. This article sheds light on this undertreatment in our country, and it is our hope that it may raise an awareness of the need for PLND in high-risk patients in Belgium. Nonetheless, it must be recognized that, to date, there is no evidence supporting an oncologic benefit of PLND for PCa patients, and this clearly excludes the possibility of better stratifying and staging patients. 37, 38 Our study is not devoid of limitations. First, we lack an open counterpart for comparing patient enrollment for open radical prostatectomy. However, data on PCa patients diagnosed between 2010 and 2012 were coupled with health insurance billing data to provide an estimate of the Original Article number of radical prostatectomies over time. These data provide details for all cancer-related therapeutic procedures, which are reimbursed by health insurance funds. Absolute numbers of open radical prostatectomy and external radiotherapy procedures did not seem change in 2010-2012. These data have to be interpreted with caution because of possible biases due to the financial implications of the billing codes. Furthermore, another limitation is represented by the absence of a central pathology review for all specimens. Moreover, an analysis of oncologic outcomes was not performed in the current study, but this will be addressed in the future. Finally, the Be-RALP cancer registry was constructed to monitor robotic radical prostatectomy; as such, we were unable to draw conclusions about the changes in the enrollment of patients undergoing active surveillance, focal therapy, and other radical treatments. Nonetheless, this study has significant strengths because it yields a contemporary picture of robotic prostatectomy practice nationwide in Belgian, with most centers adhering to the project as part of the reimbursement process for robotic materials. Moreover, the Belgian Cancer Registry independently double-checked the correctness of the pathology data, and this reduced bias.
In conclusion, in this prospective national Belgian registry, we found a significant inverse stage and grade migration of patient enrollment for RALP during the last 6 years. In particular, we observed a reduction of low-risk PCa and an increase in intermediate-and high-risk PCa. Moreover, a consequent increase in pathological, locally advanced pT3 to pT4 cancers was observed along with a reduction of Gleason 6 (3 1 3) disease, yet the PSM rate remained constant. Finally, we report an increase in the adoption of PLND at the time of RALP and a rise in node-positive disease. Further studies are needed to evaluate the impact of these modifications on the oncologic outcomes of PCa in Belgium.
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